+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 173 Pages
  • July 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5645055
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Drugs In Development, 2022, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 8, 45, 21 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 7 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Acinetobacter Infections - Overview
  • Acinetobacter Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Acinetobacter Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Acinetobacter Infections - Companies Involved in Therapeutics Development
  • Acinetobacter Infections - Drug Profiles
  • Acinetobacter Infections - Dormant Projects
  • Acinetobacter Infections - Discontinued Products
  • Acinetobacter Infections - Product Development Milestones
  • Featured News & Press Releases
  • Jun 13, 2022: Entasis Therapeutics presents data on Sulbactam-Durlobactam at 2022 ASM Microbe Annual Conference
  • May 17, 2022: Entasis Therapeutics presents data highlights from phase 3 ATTACK trial at 2022 American Thoracic Society Annual Conference
  • Apr 26, 2022: Entasis Therapeutics presents efficacy and safety data from landmark phase 3 ATTACK Trial at ECCMID 2022 Conference
  • Apr 21, 2022: Qpex Biopharma announces presentation of Clinical Data for Lipopeptide QPX9003 at ECCMID 2022 Meeting
  • Apr 18, 2022: Entasis Therapeutics presents SUL-DUR topline data from phase 3 ATTACK Trial at ECCMID 2022 Conference
  • Oct 19, 2021: Entasis reports positive data from Phase III Acinetobacter drug trial
  • Aug 10, 2021: Entasis Therapeutics to host expert perspectives webinar on Acinetobacter infections
  • Jul 27, 2021: Entasis Therapeutics and Zai Lab Complete patient enrollment in the ATTACK phase 3 registrational clinical trial of sulbactam-durlobactam
  • Jun 18, 2021: Monash University’s new antibiotic against superbugs starts US trial
  • Jun 18, 2021: Entasis Therapeutics presents data on SUL-DUR at World Microbe Forum
  • Mar 04, 2021: ARCH scientist publishes paper showing pre-clinical efficacy of AB569 in eradicating multi-drug resistant pathogens Acinetobacter baumannii and Acinetobacter spp
  • Jan 26, 2021: Entasis Therapeutics announces sulbactam-durlobactam expanded access program for patients in the U.S.
  • Oct 14, 2020: Entasis Therapeutics highlights multiple data presentations at Virtual ID Week
  • Jul 27, 2020: Venatorx Pharmaceuticals awarded up to $44.2 million to advance novel inhibitors of penicillin binding proteins targeting WHO critical priority pathogen
  • May 18, 2020: Zai Lab announces first chinese patient dosed in the global phase 3 ATTACK trial of Sulbactam-Durlobactam for patients with Carbapenem-Resistant Acinetobacter Infections
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Acinetobacter Infections, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Acinetobacter Infections - Pipeline by AbGenics Life Sciences Pvt Ltd, 2022
  • Acinetobacter Infections - Pipeline by Adaptive Phage Therapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by AGILeBiotics BV, 2022
  • Acinetobacter Infections - Pipeline by Alterity Therapeutics Ltd, 2022
  • Acinetobacter Infections - Pipeline by Antabio SAS, 2022
  • Acinetobacter Infections - Pipeline by Appili Therapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by Arch Biopartners Inc, 2022
  • Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals Inc, 2022
  • Acinetobacter Infections - Pipeline by Armata Pharmaceuticals Inc, 2022
  • Acinetobacter Infections - Pipeline by Asieris Pharmaceuticals Co Ltd, 2022
  • Acinetobacter Infections - Pipeline by AstraZeneca Plc, 2022
  • Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by Aurora Oncology Inc, 2022
  • Acinetobacter Infections - Pipeline by Bioharmony Therapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by Biological Anti-Infective Medicines LLC, 2022
  • Acinetobacter Infections - Pipeline by Biomendics LLC, 2022
  • Acinetobacter Infections - Pipeline by Bioversys AG, 2022
  • Acinetobacter Infections - Pipeline by Bugworks Research India Pvt Ltd, 2022
  • Acinetobacter Infections - Pipeline by Celdara Medical LLC, 2022
  • Acinetobacter Infections - Pipeline by Centauri Therapeutics Ltd, 2022
  • Acinetobacter Infections - Pipeline by Clarametyx Biosciences Inc, 2022
  • Acinetobacter Infections - Pipeline by ContraFect Corp, 2022
  • Acinetobacter Infections - Pipeline by Danuvius BioSciences, 2022
  • Acinetobacter Infections - Pipeline by Debiopharm International SA, 2022
  • Acinetobacter Infections - Pipeline by Entasis Therapeutics Holdings Inc, 2022
  • Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2022
  • Acinetobacter Infections - Pipeline by Fedora Pharmaceuticals Inc, 2022
  • Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, 2022
  • Acinetobacter Infections - Pipeline by Idorsia Pharmaceutical Ltd, 2022
  • Acinetobacter Infections - Pipeline by Infextious Therapeutic, 2022
  • Acinetobacter Infections - Pipeline by Inhibrx Inc, 2022
  • Acinetobacter Infections - Pipeline by KBP Biosciences Co Ltd, 2022
  • Acinetobacter Infections - Pipeline by Linnaeus Bioscience Inc, 2022
  • Acinetobacter Infections - Pipeline by Meiji Seika Pharma Co Ltd, 2022
  • Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by MetalloBio Ltd, 2022
  • Acinetobacter Infections - Pipeline by Mutabilis SA, 2022
  • Acinetobacter Infections - Pipeline by Nektr Technologies Ltd, 2022
  • Acinetobacter Infections - Pipeline by Neoculi Pty Ltd, 2022
  • Acinetobacter Infections - Pipeline by Novabiotics Ltd, 2022
  • Acinetobacter Infections - Pipeline by Omnix Medical Ltd, 2022
  • Acinetobacter Infections - Pipeline by Oxford Drug Design Ltd, 2022
  • Acinetobacter Infections - Pipeline by Pedanius Therapeutics Ltd, 2022
  • Acinetobacter Infections - Pipeline by Peptilogics Inc, 2022
  • Acinetobacter Infections - Pipeline by Pylum Biosciences Inc, 2022
  • Acinetobacter Infections - Pipeline by Qpex Biopharma Inc, 2022
  • Acinetobacter Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
  • Acinetobacter Infections - Pipeline by Redx Pharma Plc, 2022
  • Acinetobacter Infections - Pipeline by RMH Sciences LLC, 2022
  • Acinetobacter Infections - Pipeline by Shanghai Space Peptides Pharmaceutical Co Ltd, 2022
  • Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, 2022
  • Acinetobacter Infections - Pipeline by Spero Therapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by Spexis AG, 2022
  • Acinetobacter Infections - Pipeline by Summit Therapeutics Inc, 2022
  • Acinetobacter Infections - Pipeline by Techulon Inc, 2022
  • Acinetobacter Infections - Pipeline by Vaxdyn SL, 2022
  • Acinetobacter Infections - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
  • Acinetobacter Infections - Pipeline by Venus Medicine Research Centre, 2022
  • Acinetobacter Infections - Pipeline by Vitas Pharma Research Pvt Ltd, 2022
  • Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, 2022
  • Acinetobacter Infections - Dormant Projects, 2022
  • Acinetobacter Infections - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Acinetobacter Infections, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbGenics Life Sciences Pvt Ltd
  • Adaptive Phage Therapeutics Inc
  • AGILeBiotics BV
  • Alterity Therapeutics Ltd
  • Antabio SAS
  • Appili Therapeutics Inc
  • Arch Biopartners Inc
  • Aridis Pharmaceuticals Inc
  • Armata Pharmaceuticals Inc
  • Asieris Pharmaceuticals Co Ltd
  • AstraZeneca Plc
  • Atterx Biotherapeutics Inc
  • Aurora Oncology Inc
  • Bioharmony Therapeutics Inc
  • Biological Anti-Infective Medicines LLC
  • Biomendics LLC
  • Bioversys AG
  • Bugworks Research India Pvt Ltd
  • Celdara Medical LLC
  • Centauri Therapeutics Ltd
  • Clarametyx Biosciences Inc
  • ContraFect Corp
  • Danuvius BioSciences
  • Debiopharm International SA
  • Entasis Therapeutics Holdings Inc
  • F. Hoffmann-La Roche Ltd
  • Fedora Pharmaceuticals Inc
  • Hsiri Therapeutics LLC
  • Idorsia Pharmaceutical Ltd
  • Infextious Therapeutic
  • Inhibrx Inc
  • KBP Biosciences Co Ltd
  • Linnaeus Bioscience Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • MetalloBio Ltd
  • Mutabilis SA
  • Nektr Technologies Ltd
  • Neoculi Pty Ltd
  • Novabiotics Ltd
  • Omnix Medical Ltd
  • Oxford Drug Design Ltd
  • Pedanius Therapeutics Ltd
  • Peptilogics Inc
  • Pylum Biosciences Inc
  • Qpex Biopharma Inc
  • Recce Pharmaceuticals Ltd
  • Redx Pharma Plc
  • RMH Sciences LLC
  • Shanghai Space Peptides Pharmaceutical Co Ltd
  • Shionogi & Co Ltd
  • Spero Therapeutics Inc
  • Spexis AG
  • Summit Therapeutics Inc
  • Techulon Inc
  • Vaxdyn SL
  • VenatoRx Pharmaceuticals Inc
  • Venus Medicine Research Centre
  • Vitas Pharma Research Pvt Ltd
  • Xellia Pharmaceuticals ApS